MUC16 and ovarian carcinoma: In this study, we evaluated a new combination of three known biomarkers of ovarian cancer, CA125, transthyretin, and apolipoprotein A1, in an attempt to improve the sensitivity of CA125, showing that transthyretin and apolipoprotein A1 were increased the sensitivity and specificity of the CA125 in early stage ovarian cancer.